Revenue Showdown: Jazz Pharmaceuticals plc vs Arrowhead Pharmaceuticals, Inc.

Pharma Giants: Jazz vs Arrowhead Revenue Battle

__timestampArrowhead Pharmaceuticals, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20141750001172875000
Thursday, January 1, 20153820001324803000
Friday, January 1, 20161583331487973000
Sunday, January 1, 2017314077091618693000
Monday, January 1, 2018161423211890922000
Tuesday, January 1, 20191687955772161761000
Wednesday, January 1, 2020879920662363567000
Friday, January 1, 20211382870003094238000
Saturday, January 1, 20222432310003659374000
Sunday, January 1, 20232407350003834204000
Monday, January 1, 20243551000
Loading chart...

Igniting the spark of knowledge

Revenue Showdown: Jazz Pharmaceuticals vs Arrowhead Pharmaceuticals

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Jazz Pharmaceuticals plc has consistently outperformed Arrowhead Pharmaceuticals, Inc. over the past decade. Since 2014, Jazz Pharmaceuticals has seen its revenue soar by over 200%, reaching a peak of approximately $3.8 billion in 2023. In contrast, Arrowhead Pharmaceuticals, while showing significant growth, has seen its revenue increase from a modest $175,000 in 2014 to around $240 million in 2023, marking a substantial rise but still trailing behind Jazz.

A Decade of Growth

Jazz Pharmaceuticals' revenue has grown steadily, with a notable 60% increase from 2020 to 2023. Arrowhead, despite its smaller base, has shown impressive growth, particularly between 2017 and 2022, where revenue increased by over 700%. However, the data for 2024 is incomplete, leaving room for speculation on future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025